{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:16:34Z","timestamp":1783577794792,"version":"3.55.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-grade serous ovarian cancer is one of the most lethal malignancies in women, typically diagnosed at an advanced stage, treated with debulking surgery, platinum-based chemotherapy and maintenance therapy, and associated with a high risk of recurrence even after optimal treatment. Myelodysplastic syndrome is a rare but serious haematological disease which can occur after exposure to chemotherapy or PARP inhibitor therapy. Treatment of recurrent disease in patients who develop Myelodysplastic syndrome is particularly challenging due to the significant myelotoxicity associated with standard cytotoxic chemotherapy. Mirvetuximab soravtansine is an antibody-drug conjugate approved for use in platinum-resistant folate receptor alpha-positive high-grade ovarian cancer. Due to its limited myelotoxicity, it might be an interesting treatment option in patients with relevant haematologic side effects due to previous lines of chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>We report on a patient with a recurrence of platinum-sensitive ovarian cancer (platinum-free interval: 16 months) who developed Myelodysplastic syndrome and ultimately, probably an acute Myeloid Leukaemia. Chemotherapy re-challenge with platinum-based combination chemotherapy was not feasible due to persistent thrombocytopenia (CTCAE grade 3). Therefore, treatment with mirvetuximab soravtansine was initiated showing durable response with a progression-free survival of nine months. The patient\u2019s platelet count and tumor marker CA125 remained stable for nine months while she was receiving antibody-drug conjugate treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary and conclusion<\/jats:title>\n                    <jats:p>Patients with underlying haematologic disorders sometimes cannot receive platinum-based chemotherapy due to its haematotoxicity, raising the need for alternative treatments for recurrent high-grade ovarian cancer. Data from clinical trials, supported by our case, suggest that mirvetuximab soravtansine may provide a promising option, allowing durable response without worsening pre-existing thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1898036","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:23Z","timestamp":1783575263000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Durable response to mirvetuximab soravtansine in a patient with platinum-sensitive ovarian cancer and a diagnosis of myelodysplastic syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Theresa","family":"Steindl-Tomschizek","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Lucia","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Porpaczy","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Bago-Horvath","sequence":"additional","affiliation":[{"name":"Department of Pathology, Comprehensive Cancer Center, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Polterauer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Division of General Gynecology and Gynecological Oncology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00432-025-06277-9","article-title":"Global, regional, and national burden of ovarian cancer in women aged 45+ from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 Global Burden of Disease study","volume":"151","author":"Ren","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.4.216","article-title":"Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease","volume":"49","author":"Visconte","year":"2014","journal-title":"Blood Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115472","article-title":"Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: a retrospective cohort study in England","volume":"222","author":"Steventon","year":"2025","journal-title":"Eur J Cancer"},{"key":"B6","volume-title":"Elahere (mirvetuximab soravtansine): European public assessment report (EPAR)","year":"2024"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5611","article-title":"FORWARD II: a phase Ib study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha\u00a0(FR\u03b1)-positive advanced epithelial ovarian cancer, primary peritoneal, fallopian tube, or endometrial cancer","volume":"34","author":"O\u2019Malley","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-esgo.572","article-title":"2022-RA-835-ESGO AGO-OVAR 2.34\/MIROVA: a randomized phase II trial of mirvetuximab soravtansine (IMGN853) in folate receptor alpha (FR\u03b1) high recurrent ovarian cancer eligible for platinum-based chemotherapy","volume":"32","author":"Trillsch","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2513848","article-title":"Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"21","author":"Silverstein","year":"2025","journal-title":"Future Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5622","article-title":"GLORIOSA: a randomized, open-label, phase III study of mirvetuximab soravtansine with bevacizumab vs bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer","volume":"41","author":"O\u2019Malley","year":"2023","journal-title":"J Clin Oncol"},{"key":"B13","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer. Version 1.2026","year":"2026"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","article-title":"Phase III MIRASOL (GOG 3045\/ENGOT-ov55) study: initial report of mirvetuximab soravtansine vs investigator\u2019s choice of chemotherapy in platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression","volume":"41","author":"Moore","year":"2023","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.18_suppl.LBA5509","article-title":"A randomized phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO study of the Gynecologic Cancer Intergroup","volume":"27","author":"Pujade-Lauraine","year":"2009","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1785547","article-title":"Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome","volume":"16","author":"Njonou Noujiep","year":"2026","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:24Z","timestamp":1783575264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1898036"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1898036","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1898036"}}